HUTCHMED (China) Limited (HCM)
USD 15.0
(1.35%)
USD 15.0
(1.35%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -197.45 Million USD | 31.91% |
| 2022 | -289.97 Million USD | 15.58% |
| 2021 | -343.47 Million USD | -71.81% |
| 2020 | -199.92 Million USD | -126.99% |
| 2019 | -88.07 Million USD | -48.53% |
| 2018 | -59.29 Million USD | -7.27% |
| 2017 | -55.27 Million USD | -69.34% |
| 2016 | -32.64 Million USD | -280.76% |
| 2015 | 18.05 Million USD | 768.22% |
| 2014 | 2.08 Million USD | -55.22% |
| 2013 | 4.64 Million USD | 119.45% |
| 2012 | -23.88 Million USD | -0.67% |
| 2011 | -23.72 Million USD | -14.01% |
| 2010 | -20.8 Million USD | 37.87% |
| 2009 | -33.49 Million USD | -9.46% |
| 2008 | -30.6 Million USD | 34.59% |
| 2007 | -46.78 Million USD | -1483.25% |
| 2006 | -2.95 Million USD | -267.08% |
| 2005 | 1.76 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -118.25 Million USD | 40.11% |
| 2024 Q2 | -121.85 Million USD | 2.45% |
| 2023 Q3 | -201.38 Million USD | -10.14% |
| 2023 FY | -197.45 Million USD | 31.91% |
| 2023 Q1 | -182.84 Million USD | 36.94% |
| 2023 Q2 | -182.84 Million USD | 0.0% |
| 2023 Q4 | -197.45 Million USD | 1.95% |
| 2022 Q3 | -289.97 Million USD | 37.92% |
| 2022 Q1 | -467.08 Million USD | -35.99% |
| 2022 Q4 | -289.97 Million USD | 0.0% |
| 2022 FY | -289.97 Million USD | 15.58% |
| 2022 Q2 | -467.08 Million USD | 0.0% |
| 2021 Q2 | -550.74 Million USD | -78.37% |
| 2021 FY | -343.47 Million USD | -71.81% |
| 2021 Q1 | -308.76 Million USD | -54.44% |
| 2021 Q4 | -343.47 Million USD | 0.0% |
| 2021 Q3 | -343.47 Million USD | 37.63% |
| 2020 Q4 | -199.92 Million USD | 1.09% |
| 2020 Q2 | -17.22 Million USD | -107.84% |
| 2020 Q1 | 219.7 Million USD | 343.18% |
| 2020 FY | -199.92 Million USD | -126.99% |
| 2020 Q3 | -202.12 Million USD | -1073.17% |
| 2019 Q2 | -76.11 Million USD | -28.55% |
| 2019 Q4 | -90.34 Million USD | 2.86% |
| 2019 FY | -88.07 Million USD | -48.53% |
| 2019 Q1 | -59.21 Million USD | -1.59% |
| 2019 Q3 | -93 Million USD | -22.18% |
| 2018 FY | -59.29 Million USD | -7.27% |
| 2018 Q1 | 358.29 Million USD | 748.17% |
| 2018 Q4 | -58.28 Million USD | 0.0% |
| 2018 Q2 | -48.63 Million USD | -113.57% |
| 2017 Q2 | -65.68 Million USD | -21.43% |
| 2017 Q3 | -52.69 Million USD | 19.77% |
| 2017 Q1 | -54.09 Million USD | -65.7% |
| 2017 FY | -55.27 Million USD | -69.34% |
| 2017 Q4 | -55.27 Million USD | -4.9% |
| 2016 Q4 | -32.64 Million USD | -46.54% |
| 2016 FY | -32.64 Million USD | -280.76% |
| 2016 Q3 | -22.27 Million USD | 34.63% |
| 2016 Q2 | -34.07 Million USD | -79.25% |
| 2016 Q1 | -19.01 Million USD | -205.27% |
| 2015 Q1 | 11.62 Million USD | -18.47% |
| 2015 Q3 | 15.03 Million USD | 730.43% |
| 2015 Q4 | 18.05 Million USD | 20.08% |
| 2015 FY | 18.05 Million USD | 768.22% |
| 2015 Q2 | 1.81 Million USD | -84.42% |
| 2014 Q1 | 6.69 Million USD | 44.16% |
| 2014 FY | 2.08 Million USD | -55.22% |
| 2014 Q2 | -1.07 Million USD | -116.02% |
| 2014 Q4 | 14.25 Million USD | 0.0% |
| 2013 Q1 | 8.3 Million USD | 134.78% |
| 2013 FY | 4.64 Million USD | 119.45% |
| 2013 Q3 | 12.01 Million USD | 44.7% |
| 2013 Q2 | 8.3 Million USD | 0.0% |
| 2013 Q4 | 4.64 Million USD | -61.35% |
| 2012 Q3 | -30.76 Million USD | -20.31% |
| 2012 Q2 | -25.57 Million USD | 0.0% |
| 2012 FY | -23.88 Million USD | -0.67% |
| 2012 Q4 | -23.88 Million USD | 22.37% |
| 2011 FY | -23.72 Million USD | -14.01% |
| 2011 Q4 | -23.72 Million USD | 0.0% |
| 2010 Q2 | -23.67 Million USD | 0.0% |
| 2010 Q4 | -20.8 Million USD | 0.0% |
| 2010 FY | -20.8 Million USD | 37.87% |
| 2009 FY | -33.49 Million USD | -9.46% |
| 2009 Q4 | -33.49 Million USD | 0.0% |
| 2008 FY | -30.6 Million USD | 34.59% |
| 2007 FY | -46.78 Million USD | -1483.25% |
| 2006 FY | -2.95 Million USD | -267.08% |
| 2005 FY | 1.76 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 309.6% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 363.453% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 145.358% |
| Cosmos Health Inc. | 8.59 Million USD | 2398.494% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -2304.073% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 143.047% |
| Cronos Group Inc. | -663.32 Million USD | 70.232% |
| Incannex Healthcare Limited | -5.48 Million USD | -3499.964% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -1255.051% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 261.986% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -6705.545% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -1162.952% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -1162.952% |
| SCYNEXIS, Inc. | -19.35 Million USD | -920.455% |
| Safety Shot Inc | -2.28 Million USD | -8543.852% |
| Theratechnologies Inc. | 24.87 Million USD | 893.929% |
| Alpha Teknova, Inc. | 1.97 Million USD | 10102.938% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 100226.262% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 145.629% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -7735.635% |
| Dynavax Technologies Corporation | 106.63 Million USD | 285.172% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 131.675% |
| Radius Health, Inc. | 359.28 Million USD | 154.959% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -1993.994% |
| Alvotech | 1.06 Billion USD | 118.553% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | -50.928% |
| SIGA Technologies, Inc. | -148.68 Million USD | -32.806% |
| Shineco, Inc. | 29.29 Million USD | 774.141% |
| Silver Spike Investment Corp. | -32.61 Million USD | -505.483% |
| Journey Medical Corporation | -9.7 Million USD | -1933.762% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -3802.036% |
| Embecta Corp. | 1.31 Billion USD | 115.05% |
| Harrow Health, Inc. | 116.41 Million USD | 269.613% |
| Procaps Group, S.A. | 242.93 Million USD | 181.281% |
| Biofrontera Inc. | 4.05 Million USD | 4968.294% |
| DURECT Corporation | -7.65 Million USD | -2479.801% |
| PainReform Ltd. | -7.95 Million USD | -2383.748% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -488.952% |
| OptiNose, Inc. | 58.06 Million USD | 440.064% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -3707.497% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 1415.247% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 184883.687% |
| ProPhase Labs, Inc. | 19.23 Million USD | 1126.769% |
| Phibro Animal Health Corporation | 454.84 Million USD | 143.412% |
| Procaps Group S.A. | 242.93 Million USD | 181.281% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 5468.624% |
| Viatris Inc. | 17.13 Billion USD | 101.153% |
| Rockwell Medical, Inc. | 4.45 Million USD | 4531.284% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -3948.759% |
| Tilray Brands, Inc. | 158.97 Million USD | 224.205% |
| PetIQ, Inc. | 351.93 Million USD | 156.107% |
| Talphera, Inc. | -5.72 Million USD | -3351.46% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 211.369% |
| Alimera Sciences, Inc. | 55.3 Million USD | 457.009% |
| Assertio Holdings, Inc. | -32.52 Million USD | -507.021% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -13163.591% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 4782.428% |
| Hempacco Co., Inc. | 13.61 Million USD | 1550.332% |
| Alvotech | 1.06 Billion USD | 118.553% |
| Lantheus Holdings, Inc. | -96.71 Million USD | -104.175% |
| Kamada Ltd. | -46.43 Million USD | -325.267% |
| Currenc Group, Inc. | -16.57 Million USD | -1091.435% |
| Indivior PLC | -33.95 Million USD | -481.58% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 75878.09% |
| Flora Growth Corp. | -713 Thousand USD | -27593.969% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -2304.073% |
| Evolus, Inc. | 63.7 Million USD | 409.942% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 141.213% |
| Akanda Corp. | 3.9 Million USD | 5156.652% |